News Release

PHILADELPHIA — New research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son. The findings are published in the latest edition of Nature Neuroscience.

“We know that genetic factors contribute significantly to the risk of cocaine abuse, but the potential role of epigenetic influences, how certain genes related to addiction are expressed, is still relatively unknown,” said senior study author R. Christopher Pierce, PhD, associate professor of Neuroscience in Psychiatry at Penn. “This study is the first to show that the chemical effects of cocaine use can be passed down to future generations to cause a resistance to addictive behavior, indicating that paternal exposure to toxins can have profound effects on gene expression and behavior of their offspring.”

In the current study, the team used an animal model to study inherited effects of cocaine abuse. Male rats self-administered cocaine for 60 days, while controls were administered saline. The male rats were mated with females that had never been exposed to the drug. To eliminate any influence that the males' behavior would have on the pregnant females, they were separated directly after they mated.

 The rats’ offspring were monitored to see whether they would begin to self-administer cocaine when it was offered to them. The researchers discovered that male offspring of rats exposed to the drug, but not the female offspring, acquired cocaine self-administration more slowly and had decreased levels of cocaine intake relative to controls. Moreover, control animals were willing to work significantly harder for a single cocaine dose than the offspring of cocaine-addicted rats, suggesting that the rewarding effect of cocaine was decreased.  

In collaboration with Ghazaleh Sadri-Vakili, MS, PhD, from MGH, the researchers subsequently examined the animals’ brains and found that male offspring of the cocaine-addicted rats had increased levels of a protein called brain-derived neurotrophic factor (BDNF) in the prefrontal cortex, which is known to blunt the behavioral effects of cocaine.

“We were quite surprised that the male offspring of sires that used cocaine didn't like cocaine as much,” said Pierce. “We identified one change in the brain that appears to underlie this cocaine resistance effect.  But there are undoubtedly other physiological changes as well and we are currently performing more broad experiments to identify them.  We also are eager to perform similar studies with more widely used drugs of abuse such as nicotine and alcohol.”

The findings suggest that cocaine causes epigenetic changes in sperm, thereby reprogramming the information transmitted between generations.  The researchers don’t know exactly why only the male offspring received the cocaine-resistant trait from their fathers, but speculate that sex hormones such as testosterone, estrogen and/or progesterone may play a role.

The first author of the paper, Fair M. Vassoler, PhD, is a recent graduate of the Penn neuroscience graduate group. Other investigators from Penn who contributed to this work include Samantha L. White and Heath D. Schmidt.

The work was supported by grants from the National Institutes of Health (R01 DA15214, R01 DA22339, R01 DA33641, K02 DA18678, K01 DA30445, F31 DA31535, T32 DA28874 and T32 MH86599).

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: